NASDAQ:HEPA - Nasdaq - US4268973025 - Common Stock - Currency: USD
0.2875
0 (-0.86%)
The current stock price of HEPA is 0.2875 USD. In the past month the price decreased by -52.87%. In the past year, price decreased by -99.58%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 68.04 | 838.54B | ||
JNJ | JOHNSON & JOHNSON | 15.38 | 372.51B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 17.99 | 275.58B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 14.12 | 221.49B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 16.76 | 215.69B | ||
MRK | MERCK & CO. INC. | 10.62 | 208.21B | ||
PFE | PFIZER INC | 7.37 | 129.99B | ||
SNY | SANOFI-ADR | 13.59 | 128.08B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.53 | 97.47B | ||
GSK | GSK PLC-SPON ADR | 8.6 | 75.84B | ||
ZTS | ZOETIS INC | 25.92 | 68.46B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 32.67 | 47.30B |
Hepion Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Edison, New Jersey. The company went IPO on 2014-02-07. Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on artificial intelligence (AI)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (NASH), fibrotic diseases, hepatocellular carcinoma (HCC), and other chronic diseases. Its primary asset, Rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental disease models. Its drug candidate is intended to target multiple molecular pathways across the full spectrum of liver disease progression, from the triggering events that initiate disease to the pathological events that directly impair liver function and integrity. Its AI-POWR platform provides integrative, multi-variate, systems-biology bioinformatic and big-data analysis of proprietary pre-clinical and clinical data with publicly available multi-omic databases.
HEPION PHARMACEUTICALS INC
399 Thornall St
Edison NEW JERSEY 08837 US
CEO: Robert Foster
Employees: 22
Company Website: https://hepionpharma.com/
Investor Relations: http://hepionpharma.com/investors/
Phone: 17329024000
The current stock price of HEPA is 0.2875 USD. The price decreased by -0.86% in the last trading session.
The exchange symbol of HEPION PHARMACEUTICALS INC is HEPA and it is listed on the Nasdaq exchange.
HEPA stock is listed on the Nasdaq exchange.
HEPION PHARMACEUTICALS INC (HEPA) has a market capitalization of 3.16M USD. This makes HEPA a Nano Cap stock.
HEPION PHARMACEUTICALS INC (HEPA) currently has 22 employees.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
HEPA does not pay a dividend.
HEPION PHARMACEUTICALS INC (HEPA) will report earnings on 2025-05-19.
HEPION PHARMACEUTICALS INC (HEPA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-48.56).
ChartMill assigns a fundamental rating of 1 / 10 to HEPA. HEPA may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months HEPA reported a non-GAAP Earnings per Share(EPS) of -48.56. The EPS decreased by -291.26% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -817.53% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 83% to HEPA. The Buy consensus is the average rating of analysts ratings from 7 analysts.